Stock Scorecard



Stock Summary for VistaGen Therapeutics Inc (VTGN) - $2.61 as of 11/20/2024 8:51:58 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VTGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VTGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VTGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VTGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VTGN (34 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for VTGN

VistaGen Therapeutics, Inc. ( VTGN ) Reports Q2 Loss, Misses Revenue Estimates 11/8/2024 12:30:00 AM
Zymeworks Inc. ( ZYME ) Reports Q3 Loss, Lags Revenue Estimates 10/31/2024 9:20:00 PM
Biogen Inc. ( BIIB ) Q3 Earnings and Revenues Surpass Estimates 10/30/2024 12:05:00 PM
VistaGen Therapeutics ( VTGN ) Upgraded to Buy: Here's What You Should Know 10/11/2024 4:00:00 PM
All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Vistagen Therapeutics ( NASDAQ:VTGN ) 9/6/2024 7:52:00 PM
All You Need to Know About VistaGen Therapeutics ( VTGN ) Rating Upgrade to Buy 9/6/2024 4:00:00 PM
VistaGen Therapeutics, Inc. ( VTGN ) Reports Q1 Loss, Lags Revenue Estimates 8/13/2024 9:30:00 PM
Seer, Inc. ( SEER ) Reports Q2 Loss, Misses Revenue Estimates 8/8/2024 10:20:00 PM
ADC Therapeutics SA ( ADCT ) Reports Q2 Loss, Lags Revenue Estimates 8/6/2024 12:40:00 PM
This overlooked corner of women's health could be a $350 billion market opportunity 3/15/2024 6:33:00 PM

Financial Details for VTGN

Company Overview

Ticker VTGN
Company Name VistaGen Therapeutics Inc
Country USA
Description VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 2/11/2025

Stock Price History

Last Day Price 2.61
Price 4 Years Ago 58.20
Last Day Price Updated 11/20/2024 8:51:58 PM EST
Last Day Volume 234,122
Average Daily Volume 231,402
52-Week High 5.86
52-Week Low 2.57
Last Price to 52 Week Low 1.56%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -64.20
Free Cash Flow Ratio 0.74
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 13.29
Total Cash Per Share 3.51
Book Value Per Share Most Recent Quarter 3.44
Price to Book Ratio 0.79
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 83.57
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 27,843,500
Market Capitalization 72,671,535
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 50.44%
Reported EPS 12 Trailing Months -0.74
Reported EPS Past Year -0.77
Reported EPS Prior Year -2.07
Net Income Twelve Trailing Months -39,565,200
Net Income Past Year -29,362,000
Net Income Prior Year -59,248,000
Quarterly Revenue Growth YOY -34.10%
5-Year Revenue Growth -3.38%
Operating Margin Twelve Trailing Months -77.74

Balance Sheet

Total Cash Most Recent Quarter 97,600,000
Total Cash Past Year 119,200,000
Total Cash Prior Year 16,637,600
Net Cash Position Most Recent Quarter 97,600,000
Net Cash Position Past Year 119,200,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 105,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 114,286,000
Total Stockholder Equity Prior Year 12,080,000
Total Stockholder Equity Most Recent Quarter 92,974,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -33,590,500
Free Cash Flow Per Share Twelve Trailing Months -1.21
Free Cash Flow Past Year -25,813,000
Free Cash Flow Prior Year -50,244,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal 0.00
20-Day Bollinger Lower Band 2.72
20-Day Bollinger Middle Band 3.27
20-Day Bollinger Upper Band 3.83
Beta 0.78
RSI 36.37
50-Day SMA 4.09
150-Day SMA 10.94
200-Day SMA 26.78

System

Modified 11/19/2024 3:54:54 PM EST